Andriy Rusyn
Impact in
- Neurology top 10%
- Barrier Structure and Function Studies
- Gastroenterology top 10%
- Gastrointestinal Tumor Research and Treatment
Papers in
- Oncology 12
- HER2/EGFR in Cancer Research 4
- Neutropenia and Cancer Infections 3
- Colorectal Cancer Treatments and Studies 2
- Pancreatic and Hepatic Oncology Research 2
-
- Gastric Cancer Management and Outcomes 6
- Co-authors
- Martin Schüler (7 shared papers)Uğur Şahin (7 shared papers)Bohuslav Melichar (7 shared papers)Assen Dudov (7 shared papers)Ihor Vynnychenko (7 shared papers)Igor Bondarenko (6 shared papers)Florian Lordick (7 shared papers)I. Bazin (7 shared papers)
In The Last Decade
Andriy Rusyn
16 papers receiving 478 citations
Andriy Rusyn's Hit Papers
Peers
Comparison fields: 5 of 50
- Neurology 108
- Gastroenterology 61
- Oncology 285
- Pulmonary and Respiratory Medicine 212
- Immunology 108
Countries citing papers authored by Andriy Rusyn
This map shows the geographic impact of Andriy Rusyn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andriy Rusyn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andriy Rusyn more than expected).
Fields of papers citing papers by Andriy Rusyn
This network shows the impact of papers produced by Andriy Rusyn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andriy Rusyn. The network helps show where Andriy Rusyn may publish in the future.
Co-authors
The 25 scholars most cited alongside Andriy Rusyn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma Hit paper breakdown → | 2021 | 244 |
| 2 | 2017 | 94 | |
| 3 | 2016 | 35 | |
| 4 | 2019 | 25 | |
| 5 | 2016 | 18 | |
| 6 | 2019 | 16 | |
| 7 | 2019 | 14 | |
| 8 | 2016 | 9 | |
| 9 | 2017 | 9 | |
| 10 | 2017 | 7 | |
| 11 | 2017 | 5 | |
| 12 | 2016 | 4 | |
| 13 | 2016 | 2 | |
| 14 | 2023 | 1 | |
| 15 | 2017 | 1 | |
| 16 | DENTAL STATUS FEATURES IN PATIENTS DURING ANTI-CANCER CHEMOTHERAPY (TRANSCARPATHIAN ANTITUMOR CENTER EXPERIENCE). | 2020 | 1 |
About Andriy Rusyn
Andriy Rusyn is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Neurology and Genetics, having authored 16 papers that have together received 485 indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (6 papers), Barrier Structure and Function Studies (4 papers), HER2/EGFR in Cancer Research (4 papers), Radiopharmaceutical Chemistry and Applications (4 papers), Blood disorders and treatments (3 papers), Neutropenia and Cancer Infections (3 papers), Colorectal Cancer Treatments and Studies (2 papers) and Pancreatic and Hepatic Oncology Research (2 papers). The work is most often cited by research in Neurology (108 citations), Gastroenterology (61 citations), Oncology (285 citations), Pulmonary and Respiratory Medicine (212 citations) and Immunology (108 citations). Andriy Rusyn has collaborated with scholars based in Ukraine, Russia and Bulgaria. Frequent co-authors include Martin Schüler, Uğur Şahin, Bohuslav Melichar, Assen Dudov, Ihor Vynnychenko, Igor Bondarenko, Florian Lordick, I. Bazin, Christoph Huber and Ö. Türeci. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, The Lancet Oncology, European Journal of Cancer and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.